In conclusion, we report a case of MH formation after intravitreal bevacizumab injection for treatment of DME. Although the occurrence of MH after intravitreal bevacizumab injection is uncommon, physicians should be well acquainted with this complication.
Macular Hole Formation after Intravitreal Injection of Bevacizumab for Diabetic Macular Edema
Dear Editor, Macular hole (MH) formation after anti-vascular endothelial growth factor therapy (VEGF) is a rare complication. Some cases of MH development after intravitreal bevacizumab have been reported, but there has been only one reported case of MH after intravitreal anti-VEGF for treatment of diabetic macular edema (DME). We report a patient who developed an MH after intravitreal bevacizumab injection for DME and MH closure after vitrectomy.
A 56-year-old male presented with non-proliferative diabetic retinopathy in the right eye. The best-corrected visual acuity (Fig. 1B) . Optical coherence tomography (OCT) revealed a thin epiretinal membrane, serous macular detachment and intraretinal edema that was located at the outer retina (Fig. 1C) . After giving informed consent, the patient received an intravitreal 1.25 mg bevacizumab injection with a 30-gauge needle. Two weeks after injection, the BCVA in his right eye improved to 20 / 100.
OCT revealed the formation of a full thickness MH and decreasing intraretinal edema (Fig. 1D) . Four weeks after injection, the MH was still open. The patient underwent vitrectomy combined with cataract surgery and intraocular lens implantation. Internal limiting membrane peeling and gas tamponade with 20% sulfur hexafluoride were successfully performed. One month after surgery, OCT confirmed successful closure of the MH, but the serous macular detachment still remained (Fig. 1E) . The BCVA in his right eye was 20 / 100. The patient refused further treatment due to economic reasons. Six months after vitrectomy, the serous macular detachment remained unchanged (Fig. 1F) .
The responsible factors for MH formation after intravitreal 
